FDA Approves Iroko Pharma’s Lower-Dose
Nonsteroidal Anti-Inflammatory Drug Zorvolex

Oct. 21, 2013, 9:18 PM

Iroko Pharmaceuticals LLC Oct. 21 announced that the Food and Drug Administration has approved Zorvolex (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID) for treating mild to moderate acute pain in adults.

Zorvolex was approved at dosage strengths that are 20 percent lower than currently available diclofenac products, the Philadelphia-based company said.

“The approval of Zorvolex is important news for patients and for physicians who need new options for effective pain relief, and is a significant milestone for Iroko,” John Vavricka, president and chief executive officer of Iroko, said. “This marks a major achievement towards our goal of applying new technology ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.